French Regulator Fines Novo and Lilly over Weight Loss ad Campaigns
14 Articles
14 Articles
The National Medicines Agency (ANSM) has imposed a financial penalty on these laboratories which have made publicity that may mislead patients.
In France, the National Medicines Safety Agency (ANSM) sanctioned, on Monday 4 May, nearly 2 million euros for the two world's leading manufacturers of treatments for obesity, Novo Nordisk and Eli Lilly. The regulator accused them of having promoted medicines subject to compulsory prescription, a prohibited practice. Both companies are accused of having promoted indirectly their treatments for diabetes, also used against obesity.
The National Agency for the Safety of Drugs and Health Products has sanctioned the two leading manufacturers of anti-obesity treatments in the world for advertisements encouraging the general public to turn to their drugs.
It is the view of the MANSM that the campaigns of the two labs can constitute "an indirect promotion of medicines subject to compulsory medical prescription" and "valuing the use of medication as a primary response to obesity".
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
